Lymphatic dysfunction is linked to disease pathogenesis in Duchenne muscular dystrophy animal models
- PMID: 40966282
- PMCID: PMC12478126
- DOI: 10.1073/pnas.2505656122
Lymphatic dysfunction is linked to disease pathogenesis in Duchenne muscular dystrophy animal models
Abstract
Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder characterized by progressive muscle weakness and inflammation caused by mutations in the DMD gene. Chronic inflammation in DMD exacerbates the complications associated with disease progression. Since the lymphatic system plays a crucial role in regulating and resolving inflammation, our primary goal was to investigate whether lymphatics were dysregulated in skeletal muscle of DMD animals. We used the D2.mdx murine and golden retriever muscular dystrophy (GRMD) canine models, as well as mouse and rat lymphatic muscle cells (LMCs) to determine the role of dystrophin in lymphatic structure and function in skeletal muscles. Single-cell RNA sequencing data from control LMCs showed dystrophin expression, and protein results demonstrated that the 427-, 140-, and 71-kDa dystrophin isoforms were detectable in the LMCs from control mice, whereas the 427 kDa isoform was undetectable in LMCs derived from D2.mdx mice. Microlymphangiography and magnetic resonance lymphangiogram results showed a significant decrease in lymph transport in D2.mdx mice and GRMD dogs, respectively. Isolated flank lymphatic vessels from D2.mdx mice exhibited an increase in tonic contraction and a significant decrease in the phasic contractile frequency and amplitude, supporting lymphatic vessel dysfunction. The gene expression profile and immunofluorescence analyses of dystrophic muscle revealed inflammatory lymphangiogenesis in dystrophic muscle. Skeletal muscle tissues that showed improvement in function after adeno-associated virus-microdystrophin treatment also showed significant improvement in inflammatory lymphangiogenesis in GRMD dogs. Thus, these results show a linkage between lymphatic function and DMD pathogenesis that merits further investigation in DMD patients.
Keywords: Duchenne muscular dystrophy; inflammation; lymph transport; lymphatic muscle; lymphatic vessel function.
Conflict of interest statement
Competing interests statement:The authors declare no competing interest.
References
-
- Hoffman E. P., Brown R. H. Jr., Kunkel L. M., Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987). - PubMed
-
- Moran E. M., Mastaglia F. L., The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul. Disord. 24, 943–952 (2014). - PubMed
-
- Tournadre A., Miossec P., A critical role for immature muscle precursors in myositis. Nat. Rev. Rheumatol. 9, 438–442 (2013). - PubMed
-
- Manzur A. Y., Kuntzer C., Pike G. P., Swan F. M., Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst. Rev. 1, CD003725 (2008). - PubMed
-
- Mantovani A., Sica S., Sozzani P., Allavena A., Vecchi M., Locati, The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25, 677–686 (2004). - PubMed
MeSH terms
Substances
Grants and funding
- R01 AR080129/AR/NIAMS NIH HHS/United States
- R01HL175083/HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- R01AR080129/HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- HL170975/HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- 25POST1378441/American Heart Association (AHA)
LinkOut - more resources
Full Text Sources